What is Psadt Prostatecancer?

What is Psadt Prostatecancer?

A short PSA doubling time (PSADT) is known to predict both the development of metastasis (DM), prostate cancer-specific mortality (PCSM), and increased overall mortality (OM) in patients experiencing BF after RP [4–10].

What does Psadt stand for?

Among patients with biochemical recurrence after radical prostatectomy, we found previously that postoperative prostate-specific antigen doubling time (PSADT) was associated with risk of prostate cancer death.

How is Psadt calculated?

Methods: PSADT was calculated for 122 patients with androgen-independent prostate carcinoma using 2 commonly used methods: best-line fit (BLF) and first and last observations (FLO). Then, PSADT was calculated by using both a random coefficient linear (RCL) model and a random coefficient quadratic (RCQ) model.

What is the PSA doubling time Psadt?

PSA doubling time is the number of months it would take for PSA to increase two-fold. The PSA doubling time of our example patient would therefore be 48 months.

What is a high PSA velocity?

Moul and colleagues compared the traditional PSA velocity threshold value, where more than 0.75 ng/ml/year is considered high for all age groups with age-adjusted values where the threshold values were set at 0.25 ng/ml/yr for patients aged 40 to 59 and 0.50 ng/ml/yr for those aged 60 to 69.

What should PSA be after Lupron?

Many oncologists use a working definition that biochemical recurrence has occurred if PSA levels are greater than 1–2 ng/ml 12 to 18 months following initial treatment. Ideally, post-treatment PSA levels should be less than 0.5 ng/ml, but this is rare; levels of 0.6–1.4 ng/ml may occur.

What does a PSA level of 100 mean?

CONCLUSIONS. Our results suggest the possibility for a biopsy-free diagnosis of prostate cancer, with the criterion of a PSA level >100 ng/ml and evidence of advanced disease in imaging studies.

How is psadt related to prostate cancer death?

AUTHOR CONTRIBUTIONS REFERENCES Among patients with biochemical recurrence after radical prostatectomy, we found previously that postoperative prostate-specific antigen doubling time (PSADT) was associated with risk of prostate cancer death.

What is the possible role of PSA doubling time ( psadt )?

PSADT allows distinguishing subgroups of patients at high risk of distant metastases and death, which in turn may lead to a change in the further treatment strategy. Therefore, patients with short PSA doubling time should become a subgroup, in which hormonal therapy should be considered.

What is the psadt threshold for radical prostatectomy?

If validated, our findings suggest that a PSADT threshold of <6 months should be considered for stratification of patients in future clinical trials in this setting. Each year >150,000 patients in the United States will undergo radical prostatectomy (RP) for prostate cancer [ 1 ].

What is the Gleason score for psadt < 6 months?

Patients with PSADT <6 months were also more likely to have a Gleason score of 8 to 10 than patients with PSADTs >6 months (p=0.02). Using c-indices, PSADT was evaluated as a continuous variable to establish its discriminatory ability.